Laninamivir octanoate: A new long-acting neuraminidase inhibitor for the treatment of influenza

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 10, 2011, Pages 851-857

  Ikematsu, Hideyuki ^a,b   Kawai, Naoki ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Japan Physician's Association   (Japan)

Author keywords

influenza; inhale; laninamivir; long acting; neuraminidase inhibitor; single administration

Indexed keywords

INAVIR; LANINAMIVIR; LANINAMIVIR OCTANOATE; LONG ACTING DRUG; OSELTAMIVIR; PERAMIVIR; RAPIACTA; UNCLASSIFIED DRUG; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIMICROBIAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA B; NAUSEA; NONHUMAN; SEASONAL INFLUENZA; UNSPECIFIED SIDE EFFECT; VIRUS TITRATION; VOMITING;

ADMINISTRATION, INHALATION; ADULT; ANIMALS; ANTIVIRAL AGENTS; BIRDS; CAPRYLATES; CHILD; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; JAPAN; NEURAMINIDASE; OSELTAMIVIR; PRODRUGS; VIRAL PROTEINS; VIRUS REPLICATION; ZANAMIVIR;

EID: 80053629582     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.112     Document Type: Article

References (25)

1. Nichol K, D'Heilly S, Greenberg M, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin. Infect. Dis. 48(3), 292-298 (2009
2. Fleming D, Elliot A. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 23(Suppl. 1), S1-S9 (2005
3. Thompson W, Shay D, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004 (Pubitemid 39223224)
4. Takahashi M, Nagai M. Estimation of excess mortality associated with influenza epidemics specific for sex, age and cause of death in Japan during 1987-2005. Jpn. J. Hygiene 63(1), 5-19 (2008
5. Morishima T, Togashi T, Yokita S et al. Encephalitis and encephalopathy with an influenza epidemic in Japan. Clin. Infect. Dis. 35(5), 512-517 (2002
6. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eurosurveillance 13, 1-2 (2008
7. Collins PJ, Haire LF, Lin YP et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453, 1258-1261 (2008 (Pubitemid 351913590)
8. Katrina C, Chris S, Oliver K et al. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 352(9144), 1877-1881 (1998
9. Mäkelä MJ, Pauksens K, Rostila T et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study. J. Infect. 40(1), 42-48 (2000 (Pubitemid 30157772)
10. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283(8), 1016-1024 (2000 (Pubitemid 30112215)
11. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355(9218), 1845-1850 (2000 (Pubitemid 30311875)
12. Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: A multicenter study from Japan of the 2002-2003 influenza season. Clin. Infect. Dis. 40(9), 1309-1316 (2005 (Pubitemid 40570241)
13. Kawai N, Ikematsu H, Iwaki N et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: A Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin. Infect. Dis. 43(4), 439-444 (2006). . The difference in the clinical effectiveness of oseltamivir between influenza A and B has been reported in the outpatient setting. (Pubitemid 44157151)
14. Kawai N, Ikematsu H, Hirotsu N et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: A Japanese multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis. 49(12), 1828-1835 (2009
15. Kawai N, Ikematsu H, Iwaki N et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 59(3), 207-212 (2009). . The reduction of clinical effectiveness of oseltamivir to H1N1/H274Y was significant in children but not significant in adults.
16. Koyama K, Takahashi M, Oitate M et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract. Antimicrob. Agents Chemother. 53(11), 4845-4851 (2009). Long-lasting characteristics are shown in an animal model.
17. Kiso M, Kubo S, Ozawa M et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 6(2), e1000786 (2010
18. Yamashita M, Tomozawa T, Kakuta M et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 53(1), 186-192 (2009
19. Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460(7258), 1021-1025 (2009). In vivo and in vitro efficacy of neuraminidase inhibitors and a RNA polymerase inhibitor to H1N1 2009 and H5N1 is reported.
20. Kubo S, Kakuta M, Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses. Jpn. J. Antibiot. 63(5), 337-346 (2010
21. Yamashita M, Hirai T, Kubota K et al. Unique characteristics of long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) that explains its long lasting activity. Influenza Other Respi. Viruses 5(Suppl. 1), 90-123 (2011
22. Ishizuka H, Yoshiba S, Okabe H et al. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J. Clin. Pharmacol. 50(11), 1319-1320 (2010
23. Kubo S, Tomozawa T, Kakuta M et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 54(3), 1256-1264 (2010
24. Watanabe A, Chang SC, Kim MJ et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin. Infect. Dis. 51(10), 1167-1175 (2010). Prospective multicenter, double-blind, randomized control study in adults.
25. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 54(6), 2575-2582 (2010). Prospective multicenter, double-blind, randomized control study in children.